Trial Profile
Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Extended Release OROS Paliperidone (6, 9 and 12 mg/day) and Olanzapine (10mg/Day) With Open Label Extension in Treatment of Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2016
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 09 Oct 2005 New trial record.